<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39419452</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>231</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Vemurafenib inhibits the replication of diabetogenic enteroviruses in intestinal epithelial and pancreatic beta cells.</ArticleTitle><Pagination><StartPage>106021</StartPage><MedlinePgn>106021</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2024.106021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(24)00230-4</ELocationID><Abstract><AbstractText>Enteroviruses, which infect via the gut, have been implicated in type 1 diabetes (T1D) development. Prolonged faecal shedding of enterovirus has been associated with islet autoimmunity. Additionally, enteroviral proteins and viral RNA have been detected in the pancreatic islets of individuals with recent-onset T1D, implicating their possible role in beta cell destruction. Despite this, no approved antiviral drugs currently exist that specifically target enterovirus infections for utilisation in disease interventions. Drug repurposing allows for the discovery of new clinical uses for existing drugs and can expedite drug discovery. Previously, the cancer drug Vemurafenib demonstrated unprecedented antiviral activity against several enteroviruses. In the present study, we assessed the efficacy of Vemurafenib and an analogue thereof in preventing infection or reducing the replication of enteroviruses associated with T1D. We tested Vemurafenib in intestinal epithelial cells (IECs) and insulin-producing beta cells. Additionally, we established a protocol for infecting human stem cell-derived islets (SC-islets) and used Vemurafenib and its analogue in this model. Our studies revealed that Vemurafenib exhibited strong antiviral properties in IECs and a beta cell line. The antiviral effect was also seen with the Vemurafenib analogue. SC-islets expressed the viral receptors CAR and DAF, with their highest expression in insulin- and glucagon-positive cells, respectively. SC-islets were successfully infected by CVBs and the antiviral activity of Vemurafenib and its analogue was confirmed in most SC-islet batches. In summary, our observations suggest that Vemurafenib and its analogue warrant further exploration as potential antiviral agents for the treatment of enterovirus-induced diseases, including T1D.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Butrym</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge / ANA Futura, Karolinska Institutet, Alfred Nobels Allé 8, 141 52, Stockholm, Sweden. Electronic address: marta.butrym@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byvald</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge / ANA Futura, Karolinska Institutet, Alfred Nobels Allé 8, 141 52, Stockholm, Sweden. Electronic address: fabian.byvald@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanter</LastName><ForeName>Marfa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge / ANA Futura, Karolinska Institutet, Alfred Nobels Allé 8, 141 52, Stockholm, Sweden. Electronic address: m.l.blanter@lumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringqvist</LastName><ForeName>Emma E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge / ANA Futura, Karolinska Institutet, Alfred Nobels Allé 8, 141 52, Stockholm, Sweden. Electronic address: emma.ringqvist@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasylovska</LastName><ForeName>Svitlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Cell Biology, Uppsala University, BOX 571, 751 23, Uppsala, Sweden. Electronic address: svitlana.vasylovska@mcb.uu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marjomäki</LastName><ForeName>Varpu</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biological and Environmental Science, University of Jyväskylä, P.O. Box 35, FI-40014, Jyväskylä, Finland. Electronic address: varpu.s.marjomaki@jyu.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Joey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Cell Biology, Uppsala University, BOX 571, 751 23, Uppsala, Sweden. Electronic address: joey.lau@mcb.uu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Virginia M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge / ANA Futura, Karolinska Institutet, Alfred Nobels Allé 8, 141 52, Stockholm, Sweden. Electronic address: virginia.stone@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flodström-Tullberg</LastName><ForeName>Malin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge / ANA Futura, Karolinska Institutet, Alfred Nobels Allé 8, 141 52, Stockholm, Sweden. Electronic address: malin.flodstrom-tullberg@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Coxsackievirus</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Intestinal epithelial cells</Keyword><Keyword MajorTopicYN="N">Pancreatic beta cells</Keyword><Keyword MajorTopicYN="N">Type 1 diabetes</Keyword><Keyword MajorTopicYN="N">Vemurafenib</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39419452</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2024.106021</ArticleId><ArticleId IdType="pii">S0166-3542(24)00230-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle>